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Pittsburgh School of Medicine, Pittsburgh, PennsylvaniaInfertility is a prevalent condition that has insidious impacts on the infertile individuals, their families, and society, which extend far
beyond the inability to have a biological child. Lifestyle changes, fertility treatments, and assisted reproductive technology (ART) are
available to help many infertile couples achieve their reproductive goals. All of these technologies require that the infertile individual is
able to produce at least a small number of functional gametes (eggs or sperm). It is not possible for a person who does not produce
gametes to have a biological child. This review focuses on the infertile man and describes several stem cell-based methods and gene
therapy approaches that are in the research pipeline and may lead to new fertility treatment options for men with azoospermia. (FertilUse your smartphoneSteril 2016;105:256–66. 2016 The Authors. Published by Elsevier Inc. on behalf of the
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scanner” in your smartphone’s app store or app marketplace.I n vitro fertilization was pioneeredin the United Kingdom by Drs. Pat-rick Steptoe (physician) and Robert
Edwards (researcher) (1) and led to the
birth of Louise Brown (born July 25,
1978), the world's ﬁrst baby conceived
in a Petri dish. This technology has
now led to the birth of nearly ﬁve
million babies worldwide and the
2010 Nobel Prize in Medicine for Dr.
Edwards. Despite this progress in treat-
ing infertile couples, many still remain
beyond the reach of current assisted
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256they are not able to produce mature
sperm or eggs. For those couples, there
are several methods in the research
pipeline that may expand fertility op-
tions and lead to the next renaissance
in the ﬁeld of assisted reproduction.
This review focuses on experimental
options to preserve male fertility and/
or treat male factor infertility.
Spermatogenesis is an extraordi-
narily productive process that yieldsmil-
lions of sperm each day throughout the
postpubertal life of men (2). Spermato-
genesis arises from a relatively smallcember 17, 2015; published online December 30,
om National Institutes of Health and the United
sonal fees for participating in National Institutes
al fees from Elsevier as an associate editor.
Research Institute and Foundation, the Eunice
lth and Human Development grants HD075795
ional Science Foundation and gift funds from
Julie and Michael McMullen.
ens Research Institute, 204 Craft Avenue, Pitts-
pmc.edu).
0015-0282
Inc. on behalf of the American Society for Repro-
ticle under the CC BY-NC-ND license (http://pool of spermatogonial stem cells
(SSCs) that are located in the seminifer-
ous tubules of the testis (3–5). These
adult tissue stem cells (designated
Adark and Apale spermatogonia in
humans) balance self-renewing divi-
sions that maintain the stem cell pool
with differentiating divisions that insure
continuous sperm production (Fig. 1)
(6–8). Therefore, SSCs are essential for
spermatogenesis and male fertility.
Conditions that compromise the stem
cell pool, the differentiation process,
or the testicular environment (e.g.,
genetic, environmental, medical, age,
injury) can lead to subfertility or
infertility. Reﬁnements in ART,
including testicular sperm extraction
(TESE) and intracytoplasmic sperm
injection (ICSI), now allow many men
with azoospermia (no sperm in their
ejaculate) to father biological children
from rare sperm that are biopsied
directly from the testes (Fig. 2A)
(10–12). At present, there are no
options for men with azoospermia and
failed TESE to have biological children.VOL. 105 NO. 2 / FEBRUARY 2016
FIGURE 1
Human spermatogonial stem cells and spermatogenesis. (A) Spermatogenesis occurs inside the seminiferous tubules of the testis. (B) Cut-out of the
basement membrane of the seminiferous tubule. (B and C) The basement membrane of the seminiferous epithelium contains undifferentiated
(Adark and Apale) spermatogonia and differentiating type B spermatogonia. Type B spermatogonia give rise to primary spermatocytes that
enter meiosis and migrate off the basement membrane. Subsequent meiotic divisions and spermiogenesis give rise to secondary spermatocytes,
spermatids, and the terminally differentiated spermatozoa, which are released into the lumen of the seminiferous tubules. (Figure reprinted
from Valli et al.[9] with permission from Elsevier. Artwork is by Dr. Bart Phillips, National Institute of Environmental Health Sciences.)
Gassei. Experimental therapies for male factor infertility. Fertil Steril 2016.
Fertility and Sterility®Several technologies have emerged during the past two
decades that may substantially increase the number of
reproductive options available to men who do not produce
any sperm and desire to have biological children: SSC
transplantation; SSC culture; testicular tissue grafting;
testicular tissue organ culture; induced pluripotent stem
cells; the $1,000 genome; and gene therapy (Fig. 2). This
review describes two patient scenarios to illustrate how
these technologies could be used to preserve fertility and
generate or regenerate spermatogenesis in men with azoo-
spermia. The ﬁrst scenario is the prepubertal cancer patient
who cannot preserve a semen sample before initiation of
treatment and who grows up to become an infertile adult
survivor of childhood cancer. The second scenario is a
man with idiopathic nonobstructive azoospermia and no
previous comobidities.PATIENT SCENARIO 1: MEDICALLY INDUCED
(IATROGENIC) AZOOSPERMIA
Chemotherapy and radiation treatments for cancer and other
conditions can cause permanent infertility. Adult men have
the option to cryopreserve a semen sample before the initia-
tion of treatment and use this sample in the future to achieve
a pregnancy with their partner using ART (Fig. 2A) (1, 13, 14).VOL. 105 NO. 2 / FEBRUARY 2016This option is not available to prepubertal boys who are not
making sperm or to adult survivors who did not preserve
sperm before treatment. This is a signiﬁcant human health
problem because we estimate that each year in the United
States there are >4,000 male patients who will receive
treatments that put them at risk of permanent azoospermia
and did not or could not save a semen sample (Valli et al.
[8, 9]). Testicular sperm extraction may be an option for
azoospermic adult survivors of childhood cancers who did
not save semen or testicular tissue. This is possible because
a few SSCs may survive the gonadotoxic therapy and
produce focal areas of spermatogenesis in the seminiferous
tubules, which can be retrieved by biopsy. Picton and
colleagues (20) surveyed results from ﬁve centers and
reported an overall sperm recovery rate of 44% in patients
with azoospermia undergoing TESE after chemotherapy
(15–20). Prepubertal boys cannot save a semen sample
before therapy, but they do have Adark and Apale SSCs in
their testes (Fig. 1) (21) that are poised to initiate sperm
production during puberty. Several centers in the United
States and around the world are collecting (through biopsy)
and cryopreserving testicular tissue or cells with
anticipation that experimental SSC-based therapies will be
available in the future (experimental options are reviewed
later and in Fig. 2) (20, 22–27).257
FIGURE 2
Standard and experimental options to treatmale factor infertility. (A) Sperm obtained from ejaculated semen or by testicular sperm extraction (TESE)
of infertile men can be used to achieve pregnancy by intrauterine insemination (IUI), in vitro fertilization (IVF), or IVF with intracytoplasmic sperm
injection (ICSI). (B) When it is not possible to obtain sperm, testicular tissue containing spermatogonial stem cells (SSCs) can be obtained by biopsy.
Testicular tissue can be digested with enzymes to produce a cell suspension fromwhich spermatogonial stem cells can be expanded in culture and/
or transplanted into the testes of the patient. This method has the potential to regenerate spermatogenesis and possibly natural fertility.
Heterogeneous testicular cell suspensions also have the potential to undergo de novo testicular morphogenesis to produce seminiferous
tubules with a polarized epithelium surrounded by a basement membrane with germ cells inside and interstitial cells outside the tubules. Sperm
generated in the ‘‘rebuilt’’ testes can be used to fertilize eggs by ICSI. Intact testicular tissues from prepubertal males can be grafted or
xenografted under the skin or in the scrotum and produce mature sperm that can be used to fertilize eggs by ICSI. Sperm can also be
generated when immature testicular tissues are maintained in organ culture and used to fertilize eggs by ICSI. (C) Patient-speciﬁc induced
pluripotent stem (iPS) cells can be derived from patient somatic tissues (e.g., skin or blood) and differentiated into germ line stem cells (GSCs)
to be transplanted into patient testes. This method may have the potential to regenerate spermatogenesis and natural fertility. It may also be
possible to differentiate induced pluripotent stem cells into sperm that can be used to fertilize eggs by ICSI.
Gassei. Experimental therapies for male factor infertility. Fertil Steril 2016.
VIEWS AND REVIEWSPATIENT SCENARIO 2: IDIOPATHIC
NONOBSTRUCTIVE AZOOSPERMIA
About 1% of men in the general population and 10%–15% of
infertile men are azoospermic (no sperm in the ejaculate)
(28–31). Azoospermia can be classiﬁed as obstructive
(15%–20% of cases) or nonobstructive (80%–85% of cases),
which indicates a problem with spermatogenesis (30).
Nonobstructive azoospermia is characterized by
spermatogenic failure and can be subclassiﬁed as Sertoli
cell only, early or late maturation arrest, mixed atrophy, or
complete hyalinization of the seminiferous tubules. The
chances of sperm recovery by TESE from the testes of men
with ‘‘true’’ Sertoli cell only or complete hyalinization
phenotypes are very low. Sperm recovery rates from men258with uniform early maturation arrest (spermatogonia or
spermatocytes) are considerably lower (23%–41%) than
patients with late maturation arrest and/or mixed atrophy
(54%–90%) (29, 32, 33). Review of our own records and
four retrospective studies (29, 32–34) revealed that
approximately 15% of patients with nonobstructive
azoospermia and 2% of all infertile men have a uniform
maturation arrest phenotype. A diagnosis of nonobstructive
azoospermia with maturation arrest suggests that germ cells
are present, but fail to progress through meiosis and/or
spermiogenesis. Maturation arrest could be due to intrinsic
germ cell defects or extrinsic somatic/endocrine
environment defects, or both. If an underlying genetic cause
of a somatic defect can be identiﬁed, a male factorVOL. 105 NO. 2 / FEBRUARY 2016
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maturation arrest might be amenable to gene therapy using
methods that have already been described in mice
(discussed later). Improved knowledge about the genetic
basis of infertility will aid in the counseling of infertile
men; justify the development of diagnostic screens; and
may lead to the development of patient-speciﬁc treatment
options.
STEM CELL THERAPIES FOR MALE FACTOR
INFERTILITY
SSC Transplantation
Spermatogonial stem cell transplantation was described in
1994 by Ralph Brinster and colleagues (35, 36). In the initial
reports, testicular tissue was obtained from the testes of
transgenic mice with ubiquitous expression of the lacZ
transgene. The tissue was digested with enzymes and the
resulting cell suspension was transplanted into the
seminiferous tubules of infertile recipient mice. A few
months after transplantation, donor-derived spermatogenesis
could be recognized in the testes of recipient animals by X-gal
staining, which generated a blue color due to the activity of
the lacZ encoded b-galactosidase activity. One of those classic
studies reported that fertility was restored and the lacZ trans-
gene was transmitted to progeny, providing unequivocal ev-
idence that SSCs could engraft the basement membrane of
recipient seminiferous tubules and regenerate spermatogen-
esis with functional sperm (35). This approach for homolo-
gous species SSC transplantation has now been
recapitulated in rats, pigs, goats, bulls, sheep, dogs, and mon-
keys with the production of donor-derived embryos or
offspring in mice, rats, goats, sheep, and monkeys (37–48).
Functional SSCs can be obtained from the testes of all ages
from newborn to adult (39, 48, 49) and SSCs retain their
biological function after freezing and thawing (48, 50–55).
Wu and colleagues (55) demonstrated that mouse SSCs were
competent to regenerate spermatogenesis and produce
offspring after 14 years of cryostorage. Based on these
observations, it should be possible to cryopreserve testicular
tissue or cells for prepubertal boys before they initiate
cancer treatment and thaw those cells years later for
transplantation and regeneration of spermatogenesis
(Fig. 2B).Translating SSC Transplantation to the Clinic
It is not widely known that Radford and colleagues (56) had
already biopsied and cryopreserved testicular cell suspensions
for 12 adult patients with non-Hodgkin's lymphoma in 1999.
This was before the method of SSC transplantation had been
translated to any large animal species. Testicular cells were
later reintroduced into the testes of seven of those patients
(57, 58) after completion of their cancer treatments, but
their fertility status has not been reported. Nonetheless,
those reports demonstrate that patients are willing to enroll
in experimental stem cell protocols to preserve and
potentially restore their fertility. As indicated, homologousVOL. 105 NO. 2 / FEBRUARY 2016species stem cell transplants have now been performed in
several large animal models (42–47), including our report
that nonhuman primate SSCs could be frozen, thawed, and
transplanted to regenerate spermatogenesis with functional
sperm (48). Furthermore, we estimate from published reports
and personal communications that testicular tissues or cells
have been cryopreserved for several hundred patients
worldwide (9, 20, 59). Therefore, translation of the SSC
transplantation technique to the clinic appears imminent.
Although some centers are freezing testicular cell suspen-
sions (57, 60–63), most are freezing intact pieces of testicular
tissue for patients because this preserves the option for both
tissue-based and cell-based therapies in the future (see
Fig. 2) (20, 22, 23, 25, 26, 59). Biopsied testicular tissues are
typically cut into small pieces (1–9 mm3), suspended in a
dimethyl sulfoxide (DMSO)-based freezing medium and
frozen at a controlled slow rate using a programmable
freezing machine (20, 22, 23, 25, 27, 59, 61, 64). Some
centers have reported using an ethylene glycol-based freezing
medium instead of DMSO (57, 60, 65) and some centers have
reported that viability of vitriﬁed testicular tissue is similar to
tissue frozen at a controlled slow rate (66–69).SSC Culture
The testicular biopsy that can be obtained from the testes of
prepubertal boys is relatively small in size and may contain
a few SSCs. The number of SSCs that will be required to regen-
erate spermatogenesis and fertility in humans is not known,
but it is reasonable to assume that SSC numbers will need
to be expanded in culture before transplantation to ensure
robust engraftment and spermatogenesis. Methods for main-
taining mouse SSCs in culture were established in 2003/2004
and these methods were translated to rats in 2005. Cultured
rodent SSCs can be maintained in long-term culture with
exponential expansion in numbers and they can retain their
biological potential to produce spermatogenesis and restore
fertility when transplanted into the testes of infertile recipient
mice (70–73). Langenstroth and colleagues (74) reported
maintaining nonhuman primate SSCs in short-term culture
and several groups of investigators (24, 75–83) reported
culturing human SSCs for short term or long term. Each
group reporting human SSC culture used different methods
to isolate cells for culture, different feeder or matrix
substrates, different growth factor cocktails, and different
methods to assess progress. At present, no human SSC
culture method has be independently replicated by another
group and this needs to happen to move the ﬁeld forward
(Valli et al. [8, 59]). Furthermore, although transplantation
to regenerate spermatogenesis with functional sperm and
offspring is the gold standard assay for rodent SSCs, there is
not equivalent assay of human SSCs. Molecular markers
and human-to-mouse xenotransplantation may be reason-
able surrogate assays, but there is no gold standard that is
universally agreed and deployed for human SSC experimen-
tation. Perhaps de novo testicular morphogenesis and/or
decellularized testes can be developed into tools to assay
complete human spermatogenesis (discussed later).259
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Heterogeneous testicular cell suspensions (including germ
cells, Sertoli cells, peritubular myoid cells, Leydig cells, and
other interstitial cells) have the remarkable ability to reorga-
nize into normal-looking seminiferous tubules when grafted
under the skin of immune-deﬁcient recipient mice (84–88).
Dobrinski's laboratory (86, 88) reported complete
spermatogenesis when neonatal pig and sheep testis cells
were pelleted and grafted under the skin of SCID mice. Kita
and colleagues (87) obtained similar results with fetal or
neonatal mouse, rat, and pig testis cells. Furthermore, this
group of investigators mixed cultured green ﬂuorescent
protein (GFP) positive mouse SSCs with GFP negative
neonatal mouse or rat testis cells. Complete spermatogenesis
was observed in reorganized seminiferous tubules
7–10 weeks after grafting, including GFP positive round
spermatids that were recovered and used to fertilize mouse
eggs by round spermatid injection. The resulting embryos
were transferred to pseudopregnant females and resulted in
live offspring (87). In principle a similar experimental
design could be used to assay cultured human SSCs by
mixing them with human testis cells (e.g., obtained from
organ donors) and grafting them under the skin of immune
deﬁcient mice. The method could also be used to generate
sperm for clinical application. However, to our knowledge
de novo testicular morphogenesis with human testis cells
has not been reported. Furthermore, de novo testicular
morphogenesis has not been achieved using adult cells from
any species and access to human fetal or neonatal cells is
likely to be very limited. Baert and colleagues (89) recently
reported decellularizing human testes and observed that
human testis cells could inﬁltrate the three-dimensional scaf-
fold. Perhaps in future studies human testis cells can be
infused into decellularized human testis scaffold and grafted
under the skin of mice to facilitate de novo testicular
morphogenesis.Testicular Tissue Grafting and Xenografting
Honaramooz and colleagues (90) reported that testicular tis-
sue from newborn mice, rats, pigs, and goats, in which sper-
matogenesis was not yet established, could mature and
produce complete spermatogenesis when grafted under the
skin of immune-deﬁcient nude mice. The same group of in-
vestigators (91) later reported the production of live offspring
from sperm obtained from mouse testicular tissue grafts.
Fertilization-competent sperm was also produced from xeno-
grafts of prepubertal nonhuman primate testicular tissue
transplanted into mice (92). These results suggest that it
may be possible to obtain fertilization-competent sperm by
xenografting small pieces of testicular tissue from a prepuber-
tal cancer patient under the skin of mice or other animal re-
cipients, such as pigs, that are already an established source
for human food consumption, replacement heart valves (93,
94), and potentially other organs (95). Xenografting would
also circumvent the issue of malignant contamination in
cases such as leukemia where it would be unsafe to return
testicular tissue or cells back into the body of a cancer
survivor. However, the xenografting approach raises260concerns about transmission of viruses from mice, pigs, and
other species to human cells (96, 97). Also, at present there
is no evidence that xenografted human testicular tissue can
produce spermatogenesis or sperm in mice (98–103).
If malignant contamination of the testicular tissue is not a
concern, autologous testicular tissue grafting can be consid-
ered. Luetjens and colleagues (104) demonstrated that fresh
autologous testicular tissue grafts from prepubertal marmo-
sets could produce complete spermatogenesis when trans-
planted into the scrotum, but not under the skin. Frozen
and thawed grafts did not produce complete spermatogenesis
in that study, but those grafts were only transplanted under
the skin. Therefore, additional experimentation is merited.
Testicular tissue grafting or xenografting will not restore nat-
ural fertility but could generate haploid sperm that can be
used to fertilize oocytes by ICSI (Fig. 2B).Testicular Tissue Organ Culture
There is some limited evidence that haploid germ cells can be
produced in culture without the supporting structure of the
seminiferous tubules (105–107). However, fertilization has
never been reported with those putative haploid cells. In
contrast, Sato and colleagues (108, 109) reported that intact
testicular tissue pieces from newborn mice could be
maintained in organ culture and matured to produce
complete spermatogenesis with fertilization-competent
haploid germ cells. Testicular tissues were minced into pieces
(1–3 mm3) and placed in culture at the gas-to-liquid interface
on a slab of agarose that was soaked in medium. Haploid
round spermatids and sperm were recovered from the tissue
after 3–6 weeks in culture and used to fertilize mouse eggs
by ICSI. The resulting embryos were transferred to pseudo-
pregnant females and gave rise to healthy offspring that
matured to adulthood and were fertile. If testicular tissue or-
gan culture can be translated to humans, it will provide an
alternative to autologous SSC transplantation or autologous
grafting in cases where there is concern about malignant
contamination of the testicular tissue. Sato et al. (108) were
also successful in producing haploid germ cells in organ cul-
ture of frozen and thawed testicular tissues, which is particu-
larly relevant to the cancer survivor paradigm. However, the
fertilization potential of those sperm was not tested (108).
To our knowledge, human testicular tissue organ culture
with production of haploid gametes has not been reported.
As with de novo testicular morphogenesis, one of the chal-
lenges to developing human testicular tissue organ culture
is the limited access to fetal, newborn, and/or prepubertal
tissues.Pluripotent Stem Cell Technology
Induced pluripotent stem cells can be derived from any tissue
of the body using a cocktail of reprogramming factors (110,
111). Several groups of investigators (105, 107, 112–123)
have now reported that rodent, monkey, and human
pluripotent embryonic stem cells or induced pluripotent
stem cells can be differentiated into germ cells. Hayashi and
co-workers (116) reported that it is possible to differentiateVOL. 105 NO. 2 / FEBRUARY 2016
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epiblast-like cells that then give rise to primordial germ
cell-like cells when cultured in the presence of Bone Morpho-
genic Protein-4 (MBP4). The resulting germ cells were trans-
planted into the seminiferous tubules of infertile recipient
mice where they regenerated spermatogenesis and haploid
gametes that were used to fertilize mouse oocytes by ICSI.
The embryos were transferred to recipient females and live
offspring were obtained. However, some of the offspring
developed tumors in the neck area and died prematurely, sug-
gesting that further optimization of the culture and differen-
tiation protocols will be required (116). The same groups of
investigators also reported generation of epiblast-like cells
and primordial germ cell-like cells from female-induced
pluripotent stem cells. The resulting primordial germ cell-
like cells were transplanted into recipients and functional
eggs and live offspring were obtained (124). Two groups of in-
vestigators (121, 123) recently reported the differentiation of
human pluripotent stem cells into putative human primordial
germ cell-like cells, exhibiting gene expression patterns
similar to bona ﬁde human primordial germ cells. Unfortu-
nately, the human studies cannot be validated by transplan-
tation or the production of offspring. As mentioned
previously, a surrogate assay of human spermatogenic poten-
tial is needed.
At present the recommended and best approach to pre-
serve fertility is to obtain and freeze gametes or tissue before
the initiation of therapy that can damage or eliminate germ
cells (125, 126). However, if the induced pluripotent stem
cell to germ cell differentiation technology is responsibly
developed and translated to the human clinic, this fertility
preservation paradigm could change. An adult survivor of a
childhood cancer who desires to start his family and
discovers that he is infertile could theoretically produce
sperm and biological offspring from his own skin, blood, or
other somatic cell type (Fig. 2C). This scenario applies not
only to childhood cancer survivors, but all survivors or
other infertile patients who cannot preserve or produce
functional gametes.GENE THERAPIES FOR MALE FACTOR
INFERTILITY
The $1,000 Genome and Gene Therapy
It took 11 years, more than 200 scientists, and 3 billion dollars
to sequence and publish theﬁrst draft of the human genome in
2001 (127, 128). This was a monumental achievement, but the
exorbitant cost precluded sequencing of thousands ormillions
of genomes that would be necessary to uncover the genetic
basis of many human diseases. In 2004, the National Human
Genome Research Institute initiated the $1,000 genome
project to stimulate unprecedented academic/industrial
collaboration to improve speed and reduce cost of human
genome sequencing (128). In 2015, the program has nearly
achieved its goal of sequencing the whole human genome at
the cost of about $5,000 and the whole exome sequencing
at considerably less than that cost. This progress has
accelerated the discovery of genes associated with human
male factor infertility, which may in turn lead to theVOL. 105 NO. 2 / FEBRUARY 2016development of diagnostic screens and personalized
treatment plans, perhaps including gene therapy.Germ Line Gene Therapy
Methods for genetic modiﬁcation of germ line stem cells and
Sertoli cells of the testis are well-established and used
routinely in the basic research laboratory (38, 129–138).
Germ cell gene therapy is technically feasible, but mired in
ethical concerns that the genetic modiﬁcation would be
passed to progeny, thereby treating not only the infertile
patient, but all subsequent generations. This subject matter
is actively debated (139–144) and was a key topic for
discussion at an International Summit on Human Gene
Therapy that was jointly sponsored by the National
Academies of Science, the National Academy of Medicine,
the Chinese National Academy, and the Royal Society in
December 2015 (http://www.nationalacademies.org/gene-
editing/index.htm).Sertoli Cell Gene Therapy
In 2002, three groups independently demonstrated that in vivo
Sertoli cell gene therapy could reverse the infertile phenotype
in ‘‘Steel’’ mice that lack the Kit ligand in Sertoli cells (129,
130, 132). Steel mice are infertile with small testes that are
completely devoid of spermatogenesis. The testes of Steel
mice do contain rare undifferentiated spermatogonia that
fail to differentiate in the absence of the Kit ligand, similar
to the human phenotype of azoospermia with early
maturation arrest. Reciprocal transplantation experiments
revealed that the residual spermatogonia in Steel mouse
testes are competent to produce complete spermatogenesis
when transplanted into a permissive (Kit ligand positive)
environment (37). Adenovirus (130), lentivirus (129), and
electroporation (132) were used, respectively, to introduce a
functional Kit ligand gene into the Sertoli cells of Steel
mice. In all cases, spermatogenesis was partially restored
and in two cases (adenovirus and lentivirus) sperm were
recovered and used to produce offspring by ICSI and ET
(129, 130). Important, the corrective transgene was not
transmitted to offspring in either of those studies,
suggesting that it may be possible to implement Sertoli cell
gene therapy without the risk of germ line modiﬁcation.
However, a combined total of only 33 pups were evaluated
in those two studies, therefore more rigorous assessments of
germ line transmission risk are needed.
In humans, mutations in the Kit signaling pathway lead
to the Piebald condition (145), which is characterized by
patches of pale hair or skin, but is not associated with infer-
tility. However, with the increasing accessibility of whole
genome and whole exome sequencing technology, genes
associated with human male factor infertility are being re-
vealed at an increasingly rapid pace. Some examples include
the germ cell genes SOHLH1 (146, 147) and TEX11 (148, 149)
and somatic cell genes, androgen receptor (150–153), and
NR5A1 (154, 155). The successes in the Steel mouse model
may suggest that in vivo Sertoli cell gene therapies could be
developed to treat infertility of men with somatic defects,261
VIEWS AND REVIEWSincluding androgen receptor and NR5A1. These examples are
complicated because they have multiple endocrine
phenotypes. However, Bashamboo and colleagues (154)
identiﬁed NR5A1 mutations in men with spermatogenic
failure, but who were otherwise healthy and these
investigators commented that this broadens the range of
NR5A1 phenotypes, which had previously been reported in
more severe forms of gonadal dysgenesis. Similarly,
androgen receptor mutations generate a range of
phenotypes from complete sex reversal to mild phenotypes
characterized primarily by male factor infertility (150–153).
Compelling progress in basic research investigations may
justify comprehensive genetic screening of patients with
infertility to identify causative genes to facilitate counseling
and possibly develop individualized treatments.
Safety and feasibility studies will be needed in rodents,
nonhuman primates, and human cells to conﬁrm that Sertoli
cell gene therapy can be achieved without risk of germ line
transmission and to carefully map genomic integrations of
the therapeutic transgene. The risks of insertional mutagen-
esis (156, 157) may be reduced by using nonintegrating
adenoviral vectors (158) or integration-deﬁcient lentiviral
vectors (159). Safety and feasibility studies will be particu-
larly important for the human gene therapy ﬁeld, which has
already suffered serious setbacks due to unexpected adverse
outcomes in previous trials (156, 160, 161).
In conclusion, 10%–15% of couples and 12% of men in
the United States are subfertile or infertile (162, 163).
Infertility is an insidious condition that impacts not only
the ability to have biological children, but has broader
implications for psychological well-being, relationships, ﬁ-
nances (assisted reproduction and adoption can be expen-
sive), general health, and life expectancy (163–167).
Assisted reproductive technologies are available for men
who produce even a small number of sperm in their
ejaculates or testes. It is not possible for men who do not
have cryopreserved or endogenous sperm to have biological
children. This review describes several technologies that are
currently in the research pipeline and may expand fertility
options for men in the future. Each technology described in
this review has produced functional sperm and progeny in
at least one animal model, but none except SSC
transplantation has been deployed in the human fertility
clinic as of yet. In all cases, fundamental translational and
preclinical studies of safety and feasibility are still needed.
Nonhuman primates are expensive, but are amenable to
transplantation/grafting studies that produce
spermatogenesis and ART to produce progeny. Furthermore,
stem cell dynamics, spermatogenic lineage development,
and testis anatomy in nonhuman primates are similar to
human (8, 168). Human tissue/cell studies are equally
important, but challenged by limited availability of tissues
and biological assays of spermatogenic potential and sperm
function. With responsible basic, translational, and
preclinical development, we believe that it is reasonable to
expect that one or more of the experimental reproductive
technologies described in this review will impact the male
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